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Abstract
Background: This study reviews the impact of changing infection control practices at the Manchester Adult Cystic Fibrosis Centre (MACFC)
upon the epidemiology of Burkholderia species infections.
Methods: We reviewed strain and genomovar typing of all available Burkholderia isolates at our centre between 1983–2006.
Results: The incidence/prevalence of infection with Burkholderia species between 1983–1990 was below 5%/9% each year. There was a rise in
incidence/prevalence of Burkholderia species between 1991 and 1994 with a peak of 16.3%/31.2% in 1992. Following complete cohort
segregation, the incidence has fallen to below 3% for all but one year and the prevalence has gradually reduced to 9.3% in 2005. Currently, there is
an increase in the prevalence to 10.6% for the first time since 1994, predominantly due to patients with unique infections transferring into the unit
from referring centres. The presence of unique strains now exceeds transmissible strains for the first time since 1991.
Conclusions: Infection control measures including patient segregation have controlled spread of transmissible B. cenocepacia strains, but not the
acquisition of unique strains. Unique strains of Burkholderia species now account for the majority of new infections at the Manchester Adult Cystic
Fibrosis Centre.
Crown Copyright © 2008 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.
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1. Introduction
The Burkholderia cepacia complex (Bcc) encompasses a
group of inherently resistant organisms with complex taxonomy.
The organisms were first described as pulmonary pathogens in
cystic fibrosis (CF) in the late 1970s and early 1980s and were
originally known as Pseudomonas cepacia [1]. The first detailed
description of Bcc in CF was published in 1984 [2]. The name
Burkholderia cepacia replaced Pseudomonas cepacia in 1992
with the creation of the new genus Burkholderia [3]. In 1997 a
seminal paper revealed that organisms previously biochemically
identified as B. cepacia, comprise different genomovars [4], a
name used at that time to describe genomic Burkholderia
species lacking a recognizable diagnostic phenotype. Currently,
at least ten different Bcc species are recognised with more likely
to follow [5]. In the past 20 years, the growing importance of the
Bcc has been recognized by significant advances in our
knowledge of the epidemiology and clinical role of Bcc and
other related organisms.
Bcc organisms have been recognized as capable of being
transmitted between CF patients since the 1980s [2,6,7,8]. The
majority of strains of Bcc associated with cross-infection are B.
cenocepacia strains [7]. Indeed, the epidemiology of Bcc and in
particular the intercontinental spread of the highly transmissible
B. cenocepacia ET12 lineage, has served as a model for the
investigation of patient-to-patient transmission with regard to
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other CF pathogens. Evidence indicates that Bcc transmission
(but not acquisition from the natural environment) can be
significantly reduced by patient cohort segregation/isolation [9].
It is therefore accepted universally by CF centres that patients
infected with Bcc organisms should be segregated from other
CF patients.
The potential for transmission of Bcc between patients is
thought be dependent upon a number of variables. Certain
strains, especially the B. cenocepacia lineage known as ET12,
appear to be inherently more transmissible [7,9]. Social contact,
especially of a prolonged nature, can pose a risk [6,7]. Individual
host factors may play a role [10,11]. Evidence also exists for
direct and indirect environmental transmission [12]. Airborne
dissemination of the Bcc has been identified during physiother-
apy treatments [13].
The transmission of Bcc species has been described within CF
centres in many countries. There are also regional variations in
such strains with the predominant transmissible strain identified in
the United Kingdom and Canada being B. cenocepacia ET12.
This strain has been reported to “superinfect” patients who have
harboured another Bcc [14,15]. Based on such evidence, many
centres have further enhanced their infection control policies to
segregate patients with Bcc infection according to Bcc strain type.
Past studies substantially and repeatedly demonstrated worse
clinical outcomes in patients chronically infected with Bcc than
those CF patients without Bcc infection [16–19]. These
observations are highly influenced by the morbidity and mortality
associated with B. cenocepacia infection [17–20]. “Cepacia
syndrome”, a necrotising pneumonic illness with very high
mortality and limited successful therapeutic interventions
[2,9,2,21,22], is particularly associated with B cenocepacia, but
can occur with other Bcc species [15,22,23]. B. cenocepacia
infection is also associated with higher rates of mortality and
morbidity post-bilateral sequential lung transplantation [24–26].
Two recent studies have suggested that infection with some Bcc
species may not confer the same degree of increased morbidity
and mortality as B. cenocepacia [18,19].
Transient infection with Bcc species has been demonstrated
[4,9,19]. However there is no known reliable, proven eradica-
tion therapy for early Bcc infection. Thus, the most important
step in the control of Bcc infection within a CF centre remains
adherence with infection control measures that address the
potential of cross-infection through patient-to-patient spread.
The Manchester Adult CF Centre (MACFC) is a large adult
CF centre in the North-West of England. It currently provides
care to 300 adults with CF. This centre has previously docu-
mented poorer clinical outcomes in those patients with B.
cenocepacia infection [19]. This paper aims to outline the
experience in responding to a change in epidemiology of Bur-
kholderia species infection in patients treated within our centre.
2. Method
All cases of respiratory infection by Bcc species or other
Burkholderia species, including B. gladioli, have been recorded
at our centre since 1983. Microbiological surveillance for cross-
infection with Burkholderia species has been performed at our
centre since 1991. We have a policy of sending sputum for
culture on a B. cepacia selective media to the local micro-
biological laboratory at each clinic contact with the patient. All
Burkholderia species isolated are sent to the Edinburgh CF
Microbiology Laboratory and Strain Repository for confirma-
tion of species status within the Bcc by PCR-based methods,
and strain typing (fingerprinting) by pulsed-field gel electro-
phoresis (PFGE). Isolates whose PFGE profiles were identical
or differed by up to four DNA bands were considered to be
clonal and to represent strain clusters.
In 2001, all Manchester Bcc isolates stored in the repository
from 1983 onwards were identified to species level and strain
typing performed by PFGE. Since 2001, all isolates have been
prospectively identified and typed as a matter of routine clinical
practice.
Infection control measures to prevent Bcc cross-infection
were first implemented in 1991. Initially in 1991, patients with
Burkholderia species infection were cohorted into different
areas of the inpatient facility (partial cohorting). Specifically,
patients with Burkholderia species infection were admitted to
inpatient beds on the opposite side of the corridor to non-Bur-
kholderia species infected patients. There was continued patient
mixing within a day-room facility on the ward and within areas
such as the radiology department. Patients with Burkholderia
species infection attended separate outpatient clinics to other CF
patients.
From November 1993 onwards, patients with Burkholderia
species infection have been cohorted into separate wards to non-
Bcc infected patients and each inpatient has their own single
room. Patients with Burkholderia species infection have also
continued to attend a different outpatient clinic (complete cohort
segregation).
During 2000, a policy of isolation was introduced for patients
infected with all Burkholderia species. This policy involves
patients not having any contact with other patients, either at an
inpatient or outpatient level. This is achieved by patients being
admitted to single rooms during admissions and attending
outpatient appointments and being immediately isolated within
their own clinic room.
Data relating to species identification and strain typing of all
available Burkholderia species isolated at our centre from the
years 1983 to 2006 inclusive were reviewed from our database.
The MACFC Bcc database holds information including dates of
acquisition of Bcc infection, strain type, date of referral to the
centre, and deaths.
A precise definition of “transmissible” and “epidemic
strain” is difficult. For the purposes of this review, Burkhol-
deria isolates exhibiting similar PFGE patterns and displaying
evidence of cross-infection involving two or more CF patients
are termed transmissible strains [7]. Unique strains refer to
those strains with a unique profile.
3. Results
The incidence and prevalence of infection with Burkholderia
species during the period 1983–1990 varied from 3 to 5% and
4 to 9% respectively (Fig. 1).
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There was a rise in incidence and prevalence of Burkhol-
deria species between 1991 and 1994. The peak incidence of
16.3% was seen in 1992 and the peak prevalence was 31.2% in
1994 (Fig. 1). Prior to 1991, there was no evidence of Bur-
kholderia cross-infection at the MACFC. The first transmissible
strain emerged in 1991 after a Manchester patient returned from
a CF holiday camp in North America [7].
Following the introduction of complete cohort segregation at
the end of 1993, the incidence of Burkholderia species infection
has fallen to below 3% for all but one year (Fig. 1) and the
prevalence has gradually reduced to 9.3% in 2005 (Fig. 1).
Fig. 2 highlights the incidence of infection with transmissible
and unique strains of the Burkholderia species at the MACFC.
The incidence of transmissible infection peaked in 1992 at
16.3% and has reduced to less than 2% for each year since 1994.
In contrast, the incidence of infection with unique strains of
Burkholderia species has fluctuated between 1983 and 2006.
Fig. 3 demonstrates that the prevalence of transmissible
infections peaked at 21.6% in 1993/94 and fell to b5% in 2005.
In contrast, the prevalence of unique strains peaked at 9.7% in
1991, fell to 4.3% in 2005 and during 2006 increased to 6%. In
2006, an increase in the total prevalence of all Burkholderia
strains to 10.6% was seen for the first time since 1994 (Fig. 1).
This increase can be explained by patients with unique
infections transferring into the centre from other referring
centres (Fig. 3). The prevalence of unique strains of Burkhol-
deria species now exceeds that of transmissible strains for the
first time since 1991 (Fig. 3).
In the past 12 years since complete cohort segregation,
within the centre, there have been 6 cases of new infection with
transmissible B. cenocepacia strains (all ET12) and 13 with
unique strains of Burkholderia species (Fig. 4). The 6 cases of
new transmissible B. cenocepacia have included 2 patients who
chose not to comply with infection control policies and con-
tinued to socialise with other patients who harboured this
pathogen, and 2 cases of superinfection prior to the implemen-
tation of isolation by strain type. Additionally, there was an
accidental meeting of 2 patients in a lift that could explain
another new case of transmissible infection. The reason for the
other case of new acquisition of a transmissible strain remains
unclear.
For the past 6 years, there has been just 1 case of new
infection with a transmissible B. cenocepacia strain and 9 cases
of new infection with unique strains of Burkholderia species
amongst established patients of the centre (Fig. 4). The case of
new infection with a transmissible strain was superinfection by
Fig. 1. Incidence and prevalence of B. cepacia complex infection at the
Manchester Adult Cystic Fibrosis Centre, 1983–2006.
Fig. 2. Incidence of transmissible and unique strains of B. cepacia complex
infection at the centre, 1983–2006.
Fig. 3. Prevalence of transmissible and unique strains of B. cepacia complex
infection at the centre, 1983–2006.
Fig. 4. New infection amongst established patients at the centre, 1991–2006.
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the highly transmissible B. cenocepacia ET12 strain in a patient
harbouring B. multivorans who chose not to adhere to the
centre's infection control policies by socialising with another
patient infected with the epidemic B. cenocepacia strain. Of the
9 new unique infections, 5 were Burkholderia multivorans,
1 was Burkholderia cenocepacia (not ET 12) and 3 were Bur-
kholderia gladioli.
4. Discussion
This study highlights a number of important issues in re-
lation to Burkholderia species infections at CF centres. The
importance of a microbiological and molecular surveillance
program, the success of complete cohort segregation in con-
trolling spread of a transmissible strain and a subsequent change
both in the proportion of Bcc infections represented by tran-
smissible strains and other non-cenocepacia strains are sup-
ported by the study.
The introduction of partial cohorting in 1991 was in response
to a sharp increase in both the incidence and prevalence of
Burkholderia species infection within the centre. When it was
noted that the incidence and prevalence of Burkholderia species
infections continued to increase, the surveillance program al-
lowed for an appropriate modification of the infection control
policies of the centre. This led to the introduction of complete
cohort segregation in November 1993. Patients with Bcc infec-
tion were segregated into different outpatient clinics and differ-
ent wards, after the CF centre was relocated to another hospital.
In more recent times, an “isolation” approach has been adopted.
This involves patients not having any contact with other patients
admitted to the ward or within the outpatient area.
Evidence of cross-infection between CF patients and evi-
dence of superinfection with transmissible strains of Burkhol-
deria species prompted annual surveillance of all strains and
instigation of complete cohort segregation in clinics and iso-
lation on the wards of the MACFC [14,15]. Concurrently, the
UK CF Trust produced national guidelines highlighting the
importance of patient education surrounding infection control
and infection control surveillance policies and procedures [27].
If pro-active microbiological surveillance, in particular accu-
rate species identification and molecular typing had not been in
place, further spread of the transmissible strain would likely
have occurred. The obvious benefits of such a surveillance
program have been demonstrated by this study. Molecular
typing to confirm or exclude clonality allowed for the recog-
nition that transmissible strains of Burkholderia species were
responsible for the increased incidence and prevalence within
the centre. It is therefore important that any surveillance pro-
gramme includes molecular typing of bacterial isolates.
Furthermore, the recent recognition of intercontinental spread
by another highly transmissible B. cenocepacia strain (known as
B. cenocepacia strain PHDC) [28] and reported cross-infection
with B. dolosa in North American [8] have highlighted that all
CF centres should be alert to possible emergence of other
transmissible Bcc strains within their units, and these can only be
discovered by continued molecular microbiological surveillance
programs.
Surveillance programs are only of benefit if appropriate
changes in infection control policies can be introduced once a
change in epidemiology of an infectious pathogen has been
recognised. The first systematic review of the efficacy of seg-
regation and isolation of patients with Bcc infection was
published in 2005 [29]. It observed that there are no randomized
controlled trials in the area; however, most authors recommend
the segregation of patients with Bcc infection from those with-
out [29]. Similarly, a recent review paper from the Italian Cystic
Fibrosis Research Foundation performed a literature search to
examine published evidence to support segregation and iso-
lation for infection control in Bcc and P. aeruginosa-infected
patients [30]. The paper found a paucity of controlled, pro-
spective data in the area [30]. It did however conclude that the
existing retrospective data does support segregation of patients
with pathogens such as Bcc [30]. Notably, this paper did not
include Danish data, collected between 1970 and 1987, which
showed a fall in the incidence of new chronic Pseudomonas
aeruginosa infection from 17% in 1976–1980 to 3% in 1986–
1987 [31,32]. This change in the epidemiology of new chronic
P. aeruginosa infection was seen after the introduction of
elective intravenous antibiotics but before the introduction of
early treatment of intermittent P. aeruginosa infection [31]. Our
experience with complete cohort segregation and later isolation,
lends further support to the body of literature demonstrating the
efficacy of segregation in preventing patient to patient spread of
Bcc infections.
Prevention of acquisition of Bcc infection is of paramount
importance for a number of reasons. The inherent multiresis-
tance of the pathogen and the lack of evidence of successful
eradication mean that therapeutic options are more limited and
challenging [33]. The poorer clinical outcomes demonstrated
in Bcc infections, particularly those caused by transmissible
strains of Bcc, further highlights the reason for prevention of
acquisition [17–20].
This review of the MACFC's experience has demonstrated
that complete cohort segregation and isolation infection control
policies have controlled the spread of transmissible strains. It
has reinforced that complete cohort segregation has lead to a
change in the proportion of Bcc infections represented by
transmissible strains. It will be noted that cohort segregation has
not affected the sporadic acquisition of unique strains from
natural environments. Unique strains of Burkholderia species,
in particular Burkholderia multivorans now account for the
majority of new Burkholderia species infections within the unit.
The clinical challenges presented by an increase in unique
strains remain uncertain. The clinical impact of infection with
these unique strains may be different from the historical lessons
learnt from the era of transmissible strains of B. cenocepacia.
Transient infection is also more commonwith unique strains and
hence a great proportion of the initial infections with Burkhol-
deria species may not progress to chronic infection [4,9,19].
In summary, the importance of ongoing microbiological
surveillance for transmissible pathogens has been reinforced by
this review. The early detection of a change in the epidemiology
of a pathogen allows the swift implementation of appropriate
infection control policies to halt the spread of transmissible
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pathogens. The effectiveness of complete cohort segregation
and isolation as infection control policies in response to an
increase of the prevalence of transmissible strains of Burkhol-
deria species has been demonstrated. It remains to be seen what
the clinical impact of the changing epidemiology of Bcc
infection with a much greater proportion of unique strains of
non-B. cenocepacia strains will have.
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